mitoxantrone hydrochloride liposome + busulfan + cyclophosphamide

Mitoxantrone hydrochloride liposome + busulfan + cyclophosphamide is a combination chemotherapy regimen composed of three agents: - **Mitoxantrone hydrochloride liposome** is a liposomal formulation of mitoxantrone, an anthraquinone antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. The liposomal formulation aims to improve pharmacokinetics and reduce toxicity. - **Busulfan** is an alkylating agent that crosslinks DNA, inhibiting replication and transcription, commonly used in conditioning regimens for hematopoietic stem cell transplantation. - **Cyclophosphamide** is also an alkylating agent that interferes with DNA replication by forming cross-links in the DNA strands. This combination may be used as part of intensive conditioning regimens prior to allogeneic or autologous hematopoietic stem cell transplantation (HSCT), particularly for relapsed/refractory acute myeloid leukemia (AML) or aggressive lymphomas. The regimen leverages the synergistic cytotoxic effects of these agents to achieve high remission rates but carries significant risk for myelosuppression and other toxicities[1][3][4].